You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

34 items

Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.

Funded Biomarker Disease Site: Endometrium
Biomarker: P53, PR, ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma.

Funded Biomarker Disease Site: Head and Neck
Biomarker: PD-L1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.

Funded Biomarker Disease Site: Bladder/ Urothelial
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with uveal melanoma.

Funded Biomarker Disease Site: Ocular
Biomarker: GNAQ, GNA11
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing to confirm or exclude small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Funded Biomarker Disease Site: Ovary
Biomarker: SMARCA4
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network, William Osler Health System

Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Funded Biomarker Disease Site: Ovary
Biomarker: BRCA1, BRCA2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Funded Biomarker Disease Site: Breast
Biomarker: ESR1, PIK3CA
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Funded Biomarker Disease Site: Lung
Biomarker: Acquired EGFR T790M
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing to support diagnosis of sex-cord stromal tumours.

Funded Biomarker Disease Site: Ovary
Biomarker: DICER1, FOXL2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network

Pages